Fig. 4From: Pharmaceutical efficacy of harmalol in inhibiting hepatocellular carcinomaBar graph representation showing the effect of carcinogen (DEN+ CCl4) and harmalol treatment on experimental mice by measuring the serum level of liver functional enzymes. a ALP, b LDH, c bilirubin, d AST, and e ALT after different time period. Control, harmalol-treated (total 80 mg/kg B.W.), CCl4-treated, DEN-treated, DEN+CCl4-treated, pre-treatment (Pre-T) with harmalol (total 80 mg/kg B.W.) and post-treatment (Post-T) with harmalol (total 80 mg/kg B.W.) are presented here. Data are presented as mean ± SE, *P < 0.05 compared with the control group; #P < 0.05 compared with the DEN+CCl4-treated groupBack to article page